EDIT Editas Medicine Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EDIT

Price (delayed)

$2.81

Market cap

$431.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.69

Enterprise value

$320.99M

?
Relative Growth: Rel. Growth: 83
Relative Strength: Rel. Strength: 53
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 38

As a leading gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in ...

Highlights
EDIT's EPS has surged by 76% year-on-year and by 41% since the previous quarter
Editas Medicine's net income has surged by 69% YoY and by 32% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.editasmedicine.com
Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of EDIT

EDIT stock price

How has the Editas Medicine stock price performed over time
Intraday
-1.06%
1 week
-3.1%
1 month
-11.08%
1 year
-8.77%
YTD
37.07%
QTD
-13.27%

Financial performance

How have Editas Medicine's revenue and profit performed over time
Revenue
$47.01M
Gross profit
$47.01M
Operating income
-$75.86M
Net income
-$73.95M
Gross margin
100%
Net margin
-157.3%
EDIT's operating margin has surged by 74% year-on-year and by 43% since the previous quarter
The net margin has soared by 74% YoY and by 44% from the previous quarter
Editas Medicine's net income has surged by 69% YoY and by 32% QoQ
EDIT's operating income has soared by 68% year-on-year and by 30% since the previous quarter

Price vs fundamentals

How does EDIT's price correlate with its fundamentals

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation
P/E
N/A
P/B
2.61
P/S
7.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.83
EDIT's EPS has surged by 76% year-on-year and by 41% since the previous quarter
EDIT's P/B is 88% below its last 4 quarters average of 22.1 and 59% below its 5-year quarterly average of 6.4
The P/S is 70% less than the 5-year quarterly average of 23.4 but 11% more than the last 4 quarters average of 6.4
The revenue has grown by 21% since the previous quarter and by 21% year-on-year

Efficiency

How efficient is Editas Medicine business performance
EDIT's return on sales has surged by 74% year-on-year and by 44% since the previous quarter
The ROE has soared by 71% from the previous quarter and by 19% YoY
Editas Medicine's ROA has soared by 54% YoY and by 34% from the previous quarter
EDIT's return on invested capital is up by 24% since the previous quarter and by 16% year-on-year

Dividends

What is EDIT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time
EDIT's total assets is 80% higher than its total liabilities
EDIT's total assets has soared by 59% QoQ and by 13% YoY
EDIT's total liabilities is down by 31% year-on-year and by 9% since the previous quarter
The debt is 32% less than the equity
The company's debt to equity has shrunk by 96% QoQ and by 83% YoY
The debt has contracted by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.